October 25, 2023
(press release)
–
Accrol (AIM: ACRL), the UK's leading independent tissue converter, announces that all of the resolutions set out in the Notice of AGM were passed by the requisite majority at the Company's AGM, held earlier today.
Details of the proxy votes received by the Company are as follows:
| Resolution |
For |
Against |
Withheld |
| |
No. of votes |
% |
No. of votes |
% |
No. of votes |
| 1. To receive the Annual Report and Accounts |
219,819,362 |
99.97 |
65,673 |
0.03 |
0 |
| 2. To appoint BDO as Auditor and authorise the directors to fix their remuneration |
219,781,647 |
99.96 |
90,747 |
0.04 |
12,641 |
| 3. To approve the Directors' Remuneration Report |
212,665,237 |
96.72 |
7,207,157 |
3.28 |
12,641 |
| 4. To re-elect Chris Welsh as a Director |
219,334,006 |
99.75 |
548,180 |
0.25 |
2,849 |
| 5. To authorise the Directors to allot relevant securities |
219,313,827 |
99.74 |
561,635 |
0.26 |
9,573 |
| 6. To authorise the Directors to allot equity securities for cash without making a pre-emptive offer to shareholders* |
214,032,998 |
97.34 |
5,842,464 |
2.66 |
9,573 |
| 7. To authorise the Directors to make market purchases of ordinary shares* |
214,174,005 |
97.4 |
5,710,716 |
2.6 |
314 |
*Special resolution
Notes:
| 1. |
Proxy appointments which gave discretion to the Chairman of the AGM have been included in "For" total for the appropriate resolution. |
| 2. |
Votes "For" and "Against" any resolution are expressed as a percentage of votes validly cast for that resolution. |
| 3. |
A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against". |
| 4. |
The number of shares in issue on 17 October 2023 was 318,878,097 with no shares in treasury. |
| 5. |
The full text of the resolutions passed at the AGM is available in the Notice of AGM on the Company's website: https://www.accrol.co.uk/investors/company-reports-presentations-and-circulars/ |
| For further information, please contact: |
|
| |
|
| Accrol Group Holdings plc |
|
| Dan Wright, Executive Chairman |
Via Belvedere Communications |
| Gareth Jenkins, Chief Executive Officer |
|
| Chris Welsh, Chief Financial Officer |
|
| |
|
| Zeus (Nominated Adviser & Broker) |
|
| Dan Bate / Jordan Warburton |
Tel: +44 (0) 161 831 1512 |
| Dominic King |
Tel: +44 (0) 203 829 5000 |
| |
|
| Shore Capital Stockbrokers (Joint Broker) |
Tel: +44 (0) 20 7408 4090 |
| Malachy McEntyre/ Mark Percy / James Thomas / |
|
| Isobel Jones |
|
| Belvedere Communications Limited |
|
| Cat Valentine |
Tel: +44 (0) 7715 769 078 |
| Keeley Clarke |
Tel: +44 (0) 7967 816 525 |
| |
accrolpr@belvederepr.com |
Overview of Accrol
Accrol Group Holdings plc is a leading tissue converter and supplier of toilet tissues, kitchen rolls, facial tissues, and wet wipes to many of the UK's leading discounters and grocery retailers across the UK. The Group now operates from five manufacturing sites which together supply c.21.5% (volume) of the UK tissue market valued at c£2.5bn at retail sales value.
For more information, please visit www.accrol.co.uk.
Link for Accrol Today video: https://www.accrol.co.uk/our-business/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
